Genentech

The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.

Adaptive will use its T-cell receptor screening platform to identify TCRs that can be used to target individual cancer patients' neoantigens.

During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.

Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.

Microbiotica will use its metagenomics microbiome platform to help Genentech develop biomarkers, targets, and medicines for inflammatory bowel disease.

New trial data presented at ASCO highlights the utility of checkpoint inhibitors, alone or with chemotherapy, across PD-L1 expression groups.